Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.

Background Long-term persistence of immune response and safety of two doses of an A/California/07/2009 H1N1 pandemic influenza vaccine adjuvanted with AS03 (an α-tocopherol oil-in-water emulsion-based Adjuvant System) administered 21 d apart was evaluated in Japanese adults [NCT00989612]. Methods One-hundred healthy subjects aged 20-64 y (stratified [1:1] into two age strata 20-40 y and 41-64 y) received 21 d apart, two doses of AS03-adjuvanted 3.75µg haemagglutinin (HA) H1N1 2009 vaccine.

Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan.

Background And Objectives: This study evaluated the immunogenicity and safety of a novel H1N1 2009 pandemic vaccine(A/California/7/2009) in Japanese adults.

Results: Following Dose 1, seroprotection rate (HI titre ≥1:40) was 95%, seroconversion rate was 94% and the geometric mean titre (GMT) was 230.3 (geometric mean fold rise [GMFR]: 26.

Reproducibility of blood pressure variation in older ambulatory and bedridden subjects.

Objectives: We investigated the influence of ambulation on the reproducibility of circadian blood pressure variation in older nursing home residents.

Design: Ambulatory blood pressure monitoring was performed twice in 37 older nursing home residents.

Setting: Nursing home in Japan.